HGH Fragment 176-191
Metabolic- Molecular Formula
- C78H125N23O23S2
- Molar Mass
- 1,817.12 g/mol
- CAS Number
- 221231-10-3
- Purity Standard
- 99%+ (HPLC Verified)
- Amino Acid Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (identical to AOD-9604 without tyrosine modification)
Overview
HGH Fragment 176-191 is a 16-amino acid peptide corresponding to the C-terminal region of human growth hormone, identified as containing the lipolytic (fat-burning) activity of the intact hormone. This fragment represents the same sequence as AOD-9604, differing primarily in manufacturing specifications and research applications.
The fragment retains GH's ability to stimulate lipolysis while lacking the growth-promoting and diabetogenic effects of the full hormone. Research suggests it acts through mechanisms distinct from GH receptor activation, possibly involving direct effects on adipocyte metabolism and beta-3 adrenergic signaling.
The disulfide loop formed by the two cysteine residues creates a constrained structure that mimics the tertiary fold of this region in intact GH. This structural element is essential for biological activity and must be correctly formed during synthesis.
Research applications focus on understanding the molecular basis of GH's metabolic effects separate from its anabolic properties. The fragment serves as a tool for dissecting GH pharmacology and as a candidate for metabolic research where the growth-promoting effects of GH would be unwanted.
Synthesis Overview
HGH Fragment 176-191 is synthesized via Fmoc solid-phase peptide synthesis representing amino acids 176-191 of human growth hormone. The synthesis includes formation of the intramolecular Cys-Cys disulfide bridge, accomplished through controlled oxidation post-cleavage. Purification via preparative HPLC separates correct disulfide topology from mispaired variants. Final characterization includes mass spectrometry, HPLC purity, and Ellman's assay for free thiols.
Research Applications
- GH lipolytic domain mechanism studies
- Fat metabolism without GH-related growth effects research
- Adipocyte lipolysis and lipogenesis modulation investigation
- Beta-3 adrenergic receptor interaction studies
- Comparative studies with AOD-9604 and full-length GH
- Obesity and metabolic syndrome research models
Related Compounds
C187H291N45O59
4,113.58 g/mol
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has become one of the most intensely studied peptides in metabolic research. It...
View Full ProfileC225H348N48O68
4,813.45 g/mol
Tirzepatide represents a paradigm shift in metabolic peptide research as the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucago...
View Full ProfileC256H381N67O76S2
5,717.4 g/mol
Retatrutide is a first-in-class triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, representing the nex...
View Full Profile